139 related articles for article (PubMed ID: 38758487)
1. ASO Visual Abstract: The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma: An Australian Cohort.
Zijlker LP; Chen H; Spillane AJ; Gonzalez M; Pennington TE; Menzies AM; Lo SN; Ferguson P; Rawson R; Colebatch AJ; Stretch JR; Thompson JF; Ch'ng S; Nieweg O; Shannon KF; Long GV; Scolyer RA; Saw RPM; van Akkooi ACJ
Ann Surg Oncol; 2024 May; ():. PubMed ID: 38758487
[No Abstract] [Full Text] [Related]
2. Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery.
Zijlker LP; van der Burg SJC; Blank CU; Zuur CL; Klop WMC; Wouters MWMJ; van Houdt WJ; van Akkooi ACJ
Eur J Cancer; 2023 May; 185():131-138. PubMed ID: 36989829
[TBL] [Abstract][Full Text] [Related]
3. Judging the therapeutic value of lymph node dissections for melanoma.
Chan AD; Essner R; Wanek LA; Morton DL
J Am Coll Surg; 2000 Jul; 191(1):16-22; discussion 22-3. PubMed ID: 10898179
[TBL] [Abstract][Full Text] [Related]
4. A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes.
Kounalakis N; Gao D; Gonzalez R; Becker M; Lewis K; Poust J; Pearlman N; Robinson W; McCarter M
Immunotherapy; 2012 Jul; 4(7):679-86. PubMed ID: 22853754
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant in Situ and Systemic Immunotherapy with Lymph Node Cryoablation in Resectable Stage III Melanoma Metastasis: a Proof-of-Concept Study.
Braud A; Auloge P; Meyer N; Bouvrais C; Gharbi M; Lang H; Gangi A; Lipsker D
Cardiovasc Intervent Radiol; 2024 May; 47(5):567-572. PubMed ID: 38570342
[TBL] [Abstract][Full Text] [Related]
6. Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma.
Reijers ILM; Rawson RV; Colebatch AJ; Rozeman EA; Menzies AM; van Akkooi ACJ; Shannon KF; Wouters MW; Saw RPM; van Houdt WJ; Zuur CL; Nieweg OE; Ch'ng S; Klop WMC; Spillane AJ; Long GV; Scolyer RA; van de Wiel BA; Blank CU
JAMA Surg; 2022 Apr; 157(4):335-342. PubMed ID: 35138335
[TBL] [Abstract][Full Text] [Related]
7. ASO Author Reflections: Expectations in Axillary Lymph Node Dissections After Neoadjuvant Chemotherapy.
Fan B; James TA
Ann Surg Oncol; 2023 Jan; 30(1):112-113. PubMed ID: 36209331
[No Abstract] [Full Text] [Related]
8. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.
Reijers ILM; Menzies AM; van Akkooi ACJ; Versluis JM; van den Heuvel NMJ; Saw RPM; Pennington TE; Kapiteijn E; van der Veldt AAM; Suijkerbuijk KPM; Hospers GAP; Rozeman EA; Klop WMC; van Houdt WJ; Sikorska K; van der Hage JA; Grünhagen DJ; Wouters MW; Witkamp AJ; Zuur CL; Lijnsvelt JM; Torres Acosta A; Grijpink-Ongering LG; Gonzalez M; Jóźwiak K; Bierman C; Shannon KF; Ch'ng S; Colebatch AJ; Spillane AJ; Haanen JBAG; Rawson RV; van de Wiel BA; van de Poll-Franse LV; Scolyer RA; Boekhout AH; Long GV; Blank CU
Nat Med; 2022 Jun; 28(6):1178-1188. PubMed ID: 35661157
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
Eggermont AM
Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
[TBL] [Abstract][Full Text] [Related]
10. [Stage III melanoma: Sentinel node biopsy, completion lymph node dissection and prospects of adjuvant therapy. A French national survey on current and envisaged practices].
Orion C; Dinulescu M; Dalac-Rat S; Giacchero D; Jouary T; Lebbé C; Leccia MT; Maubec E; Meyer N; Mortier L; Dupuy A;
Ann Dermatol Venereol; 2020 Jan; 147(1):9-17. PubMed ID: 31761496
[TBL] [Abstract][Full Text] [Related]
11. ASO Author Reflections: Risk Stratification of Sentinel Node Metastases in Stage III Melanoma Patients in the Era of Adjuvant Systemic Therapy.
Hussain Z; Moncrieff M
Ann Surg Oncol; 2023 Mar; 30(3):1820-1821. PubMed ID: 36539582
[No Abstract] [Full Text] [Related]
12. Radar-Guided Localization and Resection for Metastatic Nodal and Soft Tissue Melanoma: A Single-Institution Retrospective Study.
Beekman KE; DePalo DK; Parker LM; Elleson KM; Mullinax JE; Sarnaik AA; Sondak VK; Zager JS
Cancer Control; 2024; 31():10732748241237907. PubMed ID: 38429650
[TBL] [Abstract][Full Text] [Related]
13. Robot-Assisted Pelvic Dissection for Enlarged Lymph Nodes in Melanoma Improves Recovery with Equivalent Oncological Outcomes to Open Pelvic Dissection.
Roshan A; Shah B; Anderson KD; Murphy S; Thomas B; McPhee AS; Lamb BW; Durrani AJ; Patel AJK
Ann Surg Oncol; 2024 Apr; 31(4):2727-2736. PubMed ID: 38177461
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma.
Versluis JM; Reijers ILM; Rozeman EA; Menzies AM; van Akkooi ACJ; Wouters MW; Ch'ng S; Saw RPM; Scolyer RA; van de Wiel BA; Schilling B; Long GV; Blank CU
Eur J Cancer; 2021 May; 148():51-57. PubMed ID: 33735809
[TBL] [Abstract][Full Text] [Related]
15. [Sentinel node biopsy and lymph node dissection in the era of new systemic therapies for malignant melanoma].
Ulmer A; Kofler L
Hautarzt; 2019 Nov; 70(11):864-869. PubMed ID: 31605168
[TBL] [Abstract][Full Text] [Related]
16. The extent of surgery for stage III melanoma: how much is appropriate?
Franke V; van Akkooi ACJ
Lancet Oncol; 2019 Mar; 20(3):e167-e174. PubMed ID: 30842060
[TBL] [Abstract][Full Text] [Related]
17. Current surgical management for melanoma.
Koizumi S; Inozume T; Nakamura Y
J Dermatol; 2024 Mar; 51(3):312-323. PubMed ID: 38149725
[TBL] [Abstract][Full Text] [Related]
18. Surgical Management of Melanoma: Advances and Updates.
Santamaria-Barria JA; Mammen JMV
Curr Oncol Rep; 2022 Nov; 24(11):1425-1432. PubMed ID: 35657482
[TBL] [Abstract][Full Text] [Related]
19. ASO Author Reflections: Reducing Axillary Lymph Node Dissections in Node-Positive Breast Cancer Patients.
van der Noordaa MEM; Vrancken Peeters MTFD
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):677-678. PubMed ID: 30474766
[No Abstract] [Full Text] [Related]
20. Increased Lymph Node Yield Is Associated With Improved Survival in Rectal Cancer Irrespective of Neoadjuvant Treatment: Results From a National Cohort Study.
Lykke J; Jess P; Roikjaer O;
Dis Colon Rectum; 2015 Sep; 58(9):823-30. PubMed ID: 26252843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
